Minna Balbas, PhD

Senior Director, Clinical Science, Loxo Oncology at Lilly, San Francisco, CA
Minna Balbas
Lab Phone
646-888-2163
Lab Fax
646-888-2595
Email
[email protected]
Dissertation
Mutation Based Resistance to Antiandrogens in Prostate Cancer (2013)
Mentor
Charles L. Sawyers, MD
Start Year
2009
End Year
2014
Education
University of California, Los Angeles
Publications

 

Balbas MD, Burgess MR, Murali R, Wongvipat J, Skaggs BJ, Mundel P, Weins A, Sawyers CL. (2014) MAGI-2 scaffold protein is critical for kidney barrier function. Proc Natl Acad Sci U S A., 111, 14876-81. PMCID: PMC4205655.

Arora V, Schenkein E, Murali R, Subudhi S, Wongvipat J, Balbas M, Shah N, Cai L, Efstathiou E, Logothetis C, Cheng D, Sawyers C. (2013) Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade. Cell, 155, 1309-1322.

Balbas M, Evans M, Hosfield D, Wongvipat J, Arora V, Watson P, Chen Y, Greene G, Shen Y, Sawyers C. (2013) Overcoming mutation-based resistance to antiandrogens with rational drug design. Elife, 2, 1-21.

Watson P, Chen Y, Balbas M, Wongvipat J, Socci N, Viale A, Kim K, Sawyers C. (2010) Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor. Proc Natl Acad Sci U S A, 107, 16759-16765.

Shah NP, Kasap C, Weier C, Balbas M, Nicoll JM, Bleickardt E, Nicaise C, Sawyers CL. (2008) Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis. Cancer Cell  14, 485-93.

 

View a full listing of Minna Balbas’ journal articles.